What is SeqMatic?
SeqMatic operates as a specialized provider of next-generation sequencing and multi-omics services, distinguishing itself through a science-first methodology. The company maintains a robust service portfolio that encompasses DNA, RNA, and single-cell sequencing, alongside advanced histopathology and bioinformatics capabilities. Operating out of a CLIA-licensed and CAP-accredited laboratory in Fremont, California, SeqMatic serves a sophisticated client base ranging from academic research institutions to large-scale corporate entities. Their market position is defined by a commitment to rapid turnaround times and personalized service, ensuring that complex genomic data requirements are met with precision and regulatory compliance.
How much funding has SeqMatic raised?
SeqMatic has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in SeqMatic
PPP
Public-Private Partnership
Undisclosed Investor
An institutional investor focused on providing capital to high-growth biotechnology firms.
Undisclosed Investor
A specialized lender providing non-dilutive capital to companies in the life sciences sector.
What's next for SeqMatic?
With this recent capital deployment, SeqMatic is well-positioned to accelerate its growth trajectory within the precision medicine and clinical diagnostics markets. The firm is expected to focus on expanding its laboratory throughput and enhancing its bioinformatics pipeline to maintain its competitive edge in the NGS space. As the industry shifts toward more integrated multi-omics approaches, SeqMatic's ability to provide end-to-end sequencing solutions will likely serve as a primary driver for future market expansion and strategic partnerships. The company remains focused on scaling its operational footprint while upholding the rigorous quality standards required for clinical-grade sequencing services.
See full SeqMatic company page
